Abstract

Weight loss and anorexia are common symptoms in cancer patients that occur prior to initiation of cancer therapy. Inflammation in the brain is a driver of these symptoms, yet cellular sources of neuroinflammation during malignancy are unknown. In a mouse model of pancreatic ductal adenocarcinoma (PDAC), we observed early and robust myeloid cell infiltration into the brain. Infiltrating immune cells were predominately neutrophils, which accumulated at a unique central nervous system entry portal called the velum interpositum, where they expressed CCR2. Pharmacologic CCR2 blockade and genetic deletion of Ccr2 both resulted in significantly decreased brain-infiltrating myeloid cells as well as attenuated cachexia during PDAC. Lastly, intracerebroventricular blockade of the purinergic receptor P2RX7 during PDAC abolished immune cell recruitment to the brain and attenuated anorexia. Our data demonstrate a novel function for the CCR2/CCL2 axis in recruiting neutrophils to the brain, which drives anorexia and muscle catabolism.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Sequencing data have been deposited in GEO under accession code GSE15006

The following data sets were generated

Article and author information

Author details

  1. Kevin Glenn Burfeind

    Pediatrics, Oregon Health & Science University, Portland, United States
    For correspondence
    burfeind@ohsu.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4192-6753
  2. Xinxia Zhu

    Pediatrics, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Mason Andrew Norgard

    Pediatrics, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Peter Robert Levasseur

    Pediatrics, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Christian Huisman

    Pediatrics, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Abigail C Buenafe

    Pediatrics, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Brennan Olson

    Pediatrics, MD/PhD Program, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Katherine A Michaelis

    Pediatrics, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3225-3649
  9. Eileen Ruth Samson Torres

    Behavioral Neuroscience, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5340-8734
  10. Sophia Jeng

    Biostatistics, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Shannon McWeeney

    Biostatistics, Knight Cancer Institute, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Jacob Raber

    Behavioral Neuroscience, Oregon Health & Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9861-9893
  13. Daniel L Marks

    Pediatrics, Oregon Health & Science University, Portland, United States
    For correspondence
    marksd@ohsu.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2675-7047

Funding

National Cancer Institute (R01CA184324-01)

  • Daniel L Marks

National Cancer Institute (R01CA217989-01)

  • Daniel L Marks

Brenden-Colson Center for Pancreatic Care

  • Daniel L Marks

National Cancer Institute (5F30CA213745)

  • Kevin Glenn Burfeind

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Yuting Ma, Suzhou Institute of Systems Medicine, China

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of Oregon Health & Science University. The protocol was approved by the Department of Comparative Medicine of Oregon Health & Science University (protocol IP00038). All surgery was performed under isofluorane anesthesia, and every effort was made to minimize suffering.

Version history

  1. Received: December 2, 2019
  2. Accepted: April 21, 2020
  3. Accepted Manuscript published: May 11, 2020 (version 1)
  4. Version of Record published: May 26, 2020 (version 2)

Copyright

© 2020, Burfeind et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,809
    Page views
  • 420
    Downloads
  • 34
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kevin Glenn Burfeind
  2. Xinxia Zhu
  3. Mason Andrew Norgard
  4. Peter Robert Levasseur
  5. Christian Huisman
  6. Abigail C Buenafe
  7. Brennan Olson
  8. Katherine A Michaelis
  9. Eileen Ruth Samson Torres
  10. Sophia Jeng
  11. Shannon McWeeney
  12. Jacob Raber
  13. Daniel L Marks
(2020)
Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer
eLife 9:e54095.
https://doi.org/10.7554/eLife.54095

Share this article

https://doi.org/10.7554/eLife.54095

Further reading

    1. Developmental Biology
    2. Immunology and Inflammation
    Amir Hossein Kayvanjoo, Iva Splichalova ... Elvira Mass
    Research Article

    During embryogenesis, the fetal liver becomes the main hematopoietic organ, where stem and progenitor cells as well as immature and mature immune cells form an intricate cellular network. Hematopoietic stem cells (HSCs) reside in a specialized niche, which is essential for their proliferation and differentiation. However, the cellular and molecular determinants contributing to this fetal HSC niche remain largely unknown. Macrophages are the first differentiated hematopoietic cells found in the developing liver, where they are important for fetal erythropoiesis by promoting erythrocyte maturation and phagocytosing expelled nuclei. Yet, whether macrophages play a role in fetal hematopoiesis beyond serving as a niche for maturing erythroblasts remains elusive. Here, we investigate the heterogeneity of macrophage populations in the murine fetal liver to define their specific roles during hematopoiesis. Using a single-cell omics approach combined with spatial proteomics and genetic fate-mapping models, we found that fetal liver macrophages cluster into distinct yolk sac-derived subpopulations and that long-term HSCs are interacting preferentially with one of the macrophage subpopulations. Fetal livers lacking macrophages show a delay in erythropoiesis and have an increased number of granulocytes, which can be attributed to transcriptional reprogramming and altered differentiation potential of long-term HSCs. Together, our data provide a detailed map of fetal liver macrophage subpopulations and implicate macrophages as part of the fetal HSC niche.

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Yuting Zhang, Min Zhang ... Guojiang Chen
    Research Article

    Marburg virus (MARV) is one of the filovirus species that cause deadly hemorrhagic fever in humans, with mortality rates up to 90%. Neutralizing antibodies represent ideal candidates to prevent or treat virus disease. However, no antibody has been approved for MARV treatment to date. In this study, we identified a novel human antibody named AF-03 that targeted MARV glycoprotein (GP). AF-03 possessed a high binding affinity to MARV GP and showed neutralizing and protective activities against the pseudotyped MARV in vitro and in vivo. Epitope identification, including molecular docking and experiment-based analysis of mutated species, revealed that AF-03 recognized the Niemann-Pick C1 (NPC1) binding domain within GP1. Interestingly, we found the neutralizing activity of AF-03 to pseudotyped Ebola viruses (EBOV, SUDV, and BDBV) harboring cleaved GP instead of full-length GP. Furthermore, NPC2-fused AF-03 exhibited neutralizing activity to several filovirus species and EBOV mutants via binding to CI-MPR. In conclusion, this work demonstrates that AF-03 represents a promising therapeutic cargo for filovirus-caused disease.